News
RHHBF
409.00
-5.77%
-25.03
Samsung Electronics invests $175 million in Element Biosciences' Series E funding round
Reuters · 7h ago
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Seeking Alpha · 9h ago
BUZZ-IDEAYA Biosciences drops on $300 mln equity raise
Reuters · 12h ago
FOCUS-Cancer vaccines based on mRNA advance, despite US cuts
Reuters · 13h ago
Roche keeps €600M Germany project on track despite industry concerns - report
Seeking Alpha · 15h ago
PRESS DIGEST-Financial Times - June 9
Reuters · 21h ago
BUZZ-IDEAYA Biosciences falls on $300 mln stock sale plans
Reuters · 1d ago
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
Reuters · 1d ago
Lakefront Biotherapeutics names Eric Hedrick chief medical officer
PUBT · 1d ago
Weekly Report: what happened at RHHBF last week (0601-0605)?
Weekly Report · 1d ago
Nurix surges 43% on up to $3B cancer drug deal with Roche
Seeking Alpha · 1d ago
BUZZ-Nurix Therapeutics jumps on $2 billion cancer drug agreement with Roche
Reuters · 1d ago
PRESS DIGEST -Wall Street Journal - June 8
Reuters · 1d ago
Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology
Benzinga · 1d ago
NURIX THERAPEUTICS ANNOUNCES GLOBAL COLLABORATION WITH ROCHE TO CO-DEVELOP AND CO-COMMERCIALIZE POTENTIAL BEST-IN-CLASS BTK DEGRADER BEXOBRUTIDEG ACROSS MALIGNANT HEMATOLOGY, IMMUNOLOGY AND NEUROLOGY
Reuters · 1d ago
BRIEF-Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint
Reuters · 4d ago
Amgen: Time For An Upgrade? Yes, I Think So
Seeking Alpha · 4d ago
Roche unit TIB MOLBIOL develops Bundibugyo Ebola PCR test in six days
PUBT · 5d ago
Roche develops PCR test for rare Bundibugyo Ebola strain in six days
PUBT · 5d ago
ROCHE CHAIRMAN SAYS PROTECTIONISM BY U.S. AND CHINA IS OUR BIGGEST GEOPOLITICAL CONCERN
Reuters · 5d ago
More
Webull provides a variety of real-time RHHBF stock news. You can receive the latest news about Roche Hldgs Ag through multiple platforms. This information may help you make smarter investment decisions.
About RHHBF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.